Published in AIDS Weekly, December 10th, 2001
"We are delighted that Merck's HIV vaccine program has advanced and that Vical's naked DNA technology remains a key component in Merck's latest efforts," said Vical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.